These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 35457152)

  • 1. The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome.
    Bednarz K; Kowalczyk K; Cwynar M; Czapla D; Czarkowski W; Kmita D; Nowak A; Madej P
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
    Cena H; Chiovato L; Nappi RE
    J Clin Endocrinol Metab; 2020 Aug; 105(8):e2695-709. PubMed ID: 32442310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.
    Bader S; Bhatti R; Mussa B; Abusanana S
    Womens Health (Lond); 2024; 20():17455057241234530. PubMed ID: 38444070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
    Ma R; Ding X; Wang Y; Deng Y; Sun A
    Medicine (Baltimore); 2021 Jun; 100(23):e26295. PubMed ID: 34115034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.
    Xing C; Li C; He B
    J Clin Endocrinol Metab; 2020 Sep; 105(9):2950-63. PubMed ID: 32490533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
    Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
    J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
    Song J; Ruan X; Gu M; Wang L; Wang H; Mueck AO
    Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.
    Niafar M; Pourafkari L; Porhomayon J; Nader N
    Arch Gynecol Obstet; 2016 Mar; 293(3):509-15. PubMed ID: 26660657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
    Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
    Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
    Han Y; Li Y; He B
    Reprod Biomed Online; 2019 Aug; 39(2):332-342. PubMed ID: 31229399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of obesity in the development of polycystic ovary syndrome.
    Motta AB
    Curr Pharm Des; 2012; 18(17):2482-91. PubMed ID: 22376149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal metabolic flexibility despite insulin resistance women with polycystic ovary syndrome.
    Adamska A; Karczewska-Kupczewska M; Nikołajuk A; Otziomek E; Górska M; Kowalska I; Strączkowski M
    Endocr J; 2013; 60(9):1107-13. PubMed ID: 23801024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
    Højlund K
    Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
    Chatzis P; Tziomalos K; Pratilas GC; Makris V; Sotiriadis A; Dinas K
    Folia Med (Plovdiv); 2018 Dec; 60(4):512-520. PubMed ID: 31188761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.
    Siamashvili M; Davis SN
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1081-1089. PubMed ID: 34015974
    [No Abstract]   [Full Text] [Related]  

  • 20. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.